Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

CC-486, the oral formulation of azacitidine (AZA), is an epigenetic modifier and DNA methyltransferase inhibitor in clinical development for treatment of hematologic malignancies. CC-486 administered for 7 days per 28-day treatment cycle was evaluated in a phase 1 dose-finding study. AZA has a short...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Leukemia
Asıl Yazarlar: Garcia-Manero, G, Gore, S D, Kambhampati, S, Scott, B, Tefferi, A, Cogle, C R, Edenfield, W J, Hetzer, J, Kumar, K, Laille, E, Shi, T, MacBeth, K J, Skikne, B
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2016
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4832070/
https://ncbi.nlm.nih.gov/pubmed/26442612
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2015.265
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller